Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal Jurnal Kedokteran Diponegoro Medicinus : Jurnal Kedokteran
Amelia, Sesa
Unknown Affiliation
Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
THE RELATION BETWEEN TYPES OF IRON CHELATORS AND FERITIN ON OSTEOCALCIN OF THALASSEMIA PATIENTS WITH REPEATED TRANSFUSIONS Amelia, Sesa; Nugroho, Trilaksana; Widyastiti, Nyoman Suci; Kholis, Fathur Nur
DIPONEGORO MEDICAL JOURNAL (JURNAL KEDOKTERAN DIPONEGORO) Vol 9, No 1 (2020): DIPONEGORO MEDICAL JOURNAL ( Jurnal Kedokteran Diponegoro )
Publisher : Faculty of Medicine, Diponegoro University, Semarang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (427.715 KB) | DOI: 10.14710/dmj.v9i1.26565

Abstract

Introduction:  Thalassemia is an inherited disorder that decrease the rate of globin synthesis. Multiple blood transfusions in thalassemia patients leading to complications of hemosiderosis and hemochromatosis. Iron chelator aims to remove excess iron in the body. High ferritin levels interfere with 25-hydroxyvitamin-D production and negatively affect bone metabolism, measured with osteocalcin (N-Mid Oc). Study aims to determine the relation between type of iron chelator and ferritin levels to osteocalcin levels in thalassemia patients with history of repeated transfusions. Method: An observational analytic cross-sectional study. Research was conducted in May - August 2019 and carried out at Red Cross Semarang, Rembang Hospital, and Purwodadi Hospital. Study subjects were 40 people, then 6 people were excluded to 34 people. Gender are 14 male and 20 female. Subjects were thalassemia patient with repeated transfusions and undergoing iron chelation therapy. Subjects that met the criteria were tested for blood to measure ferritin levels and osteocalcin levels. Results: Average ferritin levels was 2842.85 ug/L and average osteocalcin levels was 15.05 ng/mL. There was significant relation between type of iron chelator on osteocalcin levels (p=0.046), but there was no significant relation between type of iron chelator on ferritin levels (p=0.434). There was significant relation between ferritin levels and osteocalcin levels on patient with Deferasirox therapy (p=0.022), but no significant relation on patient with Deferiprone therapy (p=0.432). Conclusion: There is significant relation between the type of iron chelator on osteocalcin levels and there is significant relation between ferritin levels and osteocalcin levels on patient with Deferasirox therapy.Keywords: thalassemia,iron chelator, deferasirox, deferiprone, ferritin, osteocalcin
Hypoalbuminemia as a Predictor of Outcomes in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis Jacobs, Christin Yosefin; Nugroho, Fajar Prianto; Amelia, Sesa; Pannaausten, Davin; Almaszahra, Annisa Naufal; Prayogo, Andi Bagus; Jessica; Pranata, Jimmy Angga
Medicinus Vol. 14 No. 2 (2025): February
Publisher : Fakultas Kedokteran Universitas Pelita Harapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19166/med.v14i2.9548

Abstract

Background : In acute myeloid leukemia (AML), hypoalbuminemia has been observed at diagnosis and during treatment, often correlating with poor clinical outcomes such as reduced remission rates, increased treatment-related toxicity, and shorter overall survival (OS). This systematic review and meta-analysis aim to investigate the prognostic value of hypoalbuminemia in patients with AML. Methods : A comprehensive literature search was conducted across PubMed, EMBASE, and Scopus to identify relevant studies published up to January 5, 2025. The search strategy included a combination of Medical Subject Headings (MeSH) terms and keywords such as “hypoalbuminemia,” “acute myeloid leukemia,” “AML,” “serum albumin,” “prognosis,” and “outcomes.” Boolean operators (AND, OR) were applied to refine the search. Result : This systematic review and meta-analysis included 10 studies with a total sample size of 4,105 participants, of which 2,134 were male, comparing normal albumin levels to hypoalbuminemia across diverse populations. The meta-analysis comparing OS between AML patients with hypoalbuminemia and normal serum albumin levels shows a pooled HR of 1.08 (95% CI: 0.81–1.44). Conclusions : While this meta-analysis suggests a potential association between hypoalbuminemia and poorer OS and DFS in AML patients, the lack of statistical significance and high heterogeneity caution against definitive conclusions.
Vaccine-Based Immunotherapy for Metastatic Colorectal Cancer: A Systematic Review Amelia, Sesa; Mathlubaa, Asya; Amly, Harzalina Zilfi; Jacobs, Christin Yosefin; Halim, Kurnia; Heriawan, Timotius Ivan; Guantoro, Vincent; Putri, Hesti Andika
Medicinus Vol. 14 No. 3 (2025): June
Publisher : Fakultas Kedokteran Universitas Pelita Harapan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19166/med.v14i3.10166

Abstract

Background: Metastatic colorectal cancer (mCRC) remains a therapeutic challenge, particularly in microsatellite stable (MSS) tumors, which are largely unresponsive to current immunotherapy approaches. Vaccine-based immunotherapy offers a strategy to elicit tumor-specific immune responses in these immunologically “cold” tumors. However, clinical results have been mixed, and the efficacy and safety of cancer vaccines in mCRC remain to be clarified. Methods: A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines. Randomized controlled trials (RCTs) evaluating vaccine-based immunotherapy in mCRC were identified from PubMed, EMBASE, and Scopus as of May 2, 2025. Eligible studies included human subjects with mCRC receiving vaccine therapy with or without additional treatments, compared to standard or placebo regimens. The primary outcomes were overall survival (OS) and progression-free survival (PFS); safety was assessed by the incidence of grade ≥3 treatment-related adverse events. Result: Five RCTs comprising 804 patients met inclusion criteria. Pooled analysis showed a trend toward improved OS with vaccine-based immunotherapy (HR 0.81; 95% CI, 0.65–1.00; p = 0.05; I² = 0%), and a modest, non-significant improvement in PFS (HR 0.80; 95% CI, 0.62–1.05; p = 0.07; I² = 0%). The incidence of severe adverse events was lower with vaccine-based therapies (RR 0.31; 95% CI, 0.02–6.09; p = 0.23; I² = 90%). Conclusions: Vaccine-based immunotherapy in mCRC demonstrates potential clinical benefit, particularly in prolonging survival with a favorable safety profile. Further biomarker-driven studies are needed to optimize patient selection and therapeutic combinations.
Co-Authors Almaszahra, Annisa Naufal Amly, Harzalina Zilfi Fathur Nur Kholis Guantoro, Vincent Halim, Kurnia Heriawan, Timotius Ivan Jacobs, Christin Yosefin Jessica Mathlubaa, Asya Nugroho, Fajar Prianto Nugroho, Trilaksana Nyoman Suci Widyastiti Pannaausten, Davin Pranata, Jimmy Angga Prayogo, Andi Bagus Putri, Hesti Andika